Latest From Nektar Therapeutics
The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.
The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.
Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- Inhale Therapeutic Systems Inc.
- Nektar Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Nektar Therapeutics
- Senior Management
Howard W Robin, Pres. & CEO
Gil M Labrucherie, SVP, CFO
Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
Lisa Decker, PhD, VP, Bus. Dev.
- Contact Info
Phone: (415) 482-5300
455 Mission Bay Blvd. S.
San Francisco, CA 94158
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.